Amendments to the claims.

Please amend the claims as follows:

1-3. (canceled)

4. (previously presented) The formulation according to claim 24, wherein said liposome comprises a polyethyleneglycol derivative of diacylphosphatidylethanolamine.

5. (previously presented) The formulation according to claim 4, wherein the polyethyleneglycol has a molecular weight between about 500 and 5000 daltons.

6. (currently amended) ~~The~~ A formulation ~~according to claim 24, wherein the molar ratio is 10:3~~ which comprises an anti HLA-DR antibody molecule coupled to a liposome, said antibody molecule being selected from the group consisting of a whole antibody and an antigen binding fragment thereof, said formulation capable of binding to an HLA-DR protein present at both the surface of an infectious agent and at the membrane surface of a cell, wherein said liposome comprises a mixture of diacylphosphatidylcholine and diacylphosphatidylglycerol in a molar ratio of about 10:3 and the acyl chains are either saturated or unsaturated and 14-18 carbon atoms in length.

7. (previously presented) The formulation according to claim 4, wherein said liposome comprises a mixture of diacylphosphatidylcholine: diacylphosphatidylglycerol: diacylphosphatidylethanol-amine-polyethyleneglycol in a molar ratio of 10:3:0.1-3.

8. (previously presented) The formulation according to claim 24, wherein said liposome comprises a mixture of dipalmitoylphosphatidylcholine:dipalmitoylphosphatidylglycerol in a molar ratio of 10:3 or distearoylphosphatidylcholine:distearoylphosphatidylglycerol in a molar ratio of 10:3.

9. (currently amended) ~~The~~ A formulation ~~according to claim 24,~~ which comprises an anti-HLA-DR antibody molecule coupled to a liposome, said antibody molecule being selected from the group consisting of a whole antibody and an antigen binding fragment thereof, said formulation capable of binding to an HLA-DR protein present at both the surface of an infectious agent and at the membrane surface of a cell, wherein said liposome comprises a mixture of dipalmitoylphosphatidylcholine:dipalmitoylphosphatidylglycerol: dipalmitoylphosphatidylethanolamine-polyethyleneglycol in a molar ratio of 10:3:0.33 or dipalmitoylphosphatidylcholine: dipalmitoylphosphatidylglycerol: distearoylphosphatidylethanolamine-polyethyleneglycol in a molar ratio of 10:3:0.83.

10. (previously presented) The formulation according to claim 24, further comprising an additional antibody molecule to one or more proteins selected from a histocompatibility complex protein, a membrane ATPase, thy-1, an interleukin receptor, annexin II, CD3 (T3), CD4 (T4), CD5 (Ti), CD6 (T12), CD8 (T8), CD11a (LFA-1), CD11b (Mac-1), CD11c (gp150,95), CD1 (Lewis X), CD18, CD19, CD25 (Tac), CD30 (Ki-1), CD43 (leukosialin, sialophorin), CD44 (Pgp-1), CD48 (Blast-1), CD54 (ICAM-1), CD55 (DAF), CD59 (protectin, Mac inhibitor), CD63, CD71 (transferrin receptor), CDw108(GR2), cyclophilin A, cytoskeletal proteins and ß 2-microglobulin.

11. (canceled)

12. (previously presented) The formulation according to claim 24, which further comprises a drug effective against a disease or against the symptoms of a disease caused by said an infectious agent.

13. (previously presented) The formulation according to claim 24, wherein said HLA-DR protein is present at the membrane surface of a lymphoid cell or a cell of the reticuloendothelial system.

14. (previously presented) The formulation according to claim 12, wherein said HLA-DR protein is present at the membrane surface of a lymphoid cell or a cell of the reticuloendothelial system.

15. (previously presented) The formulation according to claim 13, wherein said HLA-DR protein is acquired by HIV.

16. (previously presented) The formulation according to claim 14, wherein said HLA-DR protein is acquired by HIV.

17. (previously presented) The formulation according to claim 13, further comprising an additional antibody molecule to one or more of CD4, MHC-I and CD54 proteins.

18. (previously presented) The formulation according to claim 14, further comprising an additional antibody molecule to one or more of CD4, MHC-I and CD54 proteins.

19. (previously presented) The formulation according to claim 12, wherein said drug is selected from AZT, ddI, ddC, 3TC, indinavir, saquinavir, ritonavir, nelfinavir, ganciclovir, foscarnet, ribavirin, amphotericin B and nystatin A.

20. (previously presented) The formulation according to claim 24, wherein said antibody molecule is an anti-Fab' antibody fragment directed against a HLA-DR protein.

21 – 23. (canceled)

24. (currently amended) A formulation which comprises an anti HLA-DR antibody molecule coupled to a liposome, said antibody molecule being selected from the group consisting of a whole antibody and an antigen binding fragment thereof, said formulation capable of binding to an HLA-DR protein present at both the surface of an infectious agent and at the membrane surface of a cell, wherein said liposome comprises a mixture of diacylphosphatidylcholine and

diacylphosphatidylglycerol in a molar ratio of ~~about~~ between 10:1 to 1:1 and the acyl chains are either saturated or unsaturated and 14-18 carbon atoms in length.

25. (previously presented) The formulation of claim 24, wherein said infectious agent is HIV.

26. (currently amended) A formulation which comprises an anti HLA-DR antibody molecule coupled to a liposome, said antibody molecule being selected from the group consisting of a whole antibody and an antigen binding fragment thereof, said formulation capable of binding to an HLA-DR protein present at both the surface of an infectious agent and at the membrane surface of a cell and of delivering a drug to said cell and infectious agent, wherein said liposome comprises a mixture of diacylphosphatidylcholine and diacylphosphatidylglycerol in a molar ratio of ~~about~~ between 10:1 to 1:1 and the acyl chains are either saturated or unsaturated and 14-18 carbon atoms in length.

27. (previously presented) The formulation of claim 26, wherein said infectious agent is HIV.